AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04524858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-450
Description: Oral, small molecule MK2 inhibitor
Study NCT01204749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: Weekly Intravenous (IV) AMG 386 15 mg/kg
Study NCT01204749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 386 Placebo
Description: Weekly Intravenous (IV) placebo 15 mg/kg
Study NCT01204749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
Study NCT01204749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
Study NCT04333368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord Wharton's jelly-derived human
Description: Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 60 minutes, using tubing with a 200-μm filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5.
Study NCT04333368 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5
Study NCT00549640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: 54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
Study NCT00549640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
Study NCT03980249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol: Start at 6.26 mg PO twice daily for 1-2 weeks and if tolerated, will be increased to 12.5 mg PO twice daily for 6 cycles as tolerated.
Study NCT00330759 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 120 milligrams by subcutaneous injection every 4 weeks
Study NCT00330759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: 4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
Study NCT00006252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3)
Study NCT00006252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)
Study NCT00006252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBSC
Description: 2-8,000,000/kg CD34+ cells via infusion on Day 0
Study NCT00006252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 ug/kg/day subQ injection until ANC > 1000/uL for 3 days beginning Day 5
Study NCT00006252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocytes
Description: 10,000,000 CD3+ cells/kg via infusion
Study NCT03639363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate soap-like solution
Description: 1. humidify the whole body surface with the exception of the face using water-impregnated washcloths~2. use 4% CHG-impregnated washcloths to bath the whole body surface with the exception of the face; use at least 30 ml of 4% CHG~3. wait for at least 30 seconds~4. rinse using water-impregnated washcloths
Study NCT03639363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard soap
Description: 1. humidify the whole body surface with the exception of the face using water-impregnated washcloths~2. use standard soap-impregnated washcloths to bath the whole body surface with the exception of the face~3. wait for at least 30 seconds~4. rinse using water-impregnated washcloths
Study NCT00803283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromprphone Hydrochloride (HCl) OROS
Description: Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
Study NCT00803283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sustain Release (SR)
Description: Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
Study NCT03661203 — intervention group
Intervention type: BEHAVIORAL
Intervention: self questionnaire
Description: online self questionnaire following focus group or individual interview For qualitative group only
Study NCT01999296 — intervention group
Intervention type: DEVICE
Intervention: Use of Thunderbeat (TM) in laparoscopic surgery
Study NCT01187940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEGASUS
Description: PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
Study NCT01155336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza®
Description: Lovaza® is prescription grade EPA+DHA fish oil supplement.
Study NCT02842320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological samples
Description: bone marrow and blood
Study NCT02437253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subjects will be treated with adalimumab (20 mg \[weight 15-\<30 kg\] or 40 mg \[weight ≥30 kg\] administered subcutaneously \[subQ\] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
Study NCT01155336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo contained 1 gram of corn oil in each capsule.
Description: Placebo Pill
Study NCT05437523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constipation Action Plan
Description: The author team previously developed and assessed this constipation action plan using the universal precautions approach to produce a tool which could optimize knowledge transfer from clinicians to patients, and support stepwise home self-management of functional constipation. The Uniformed Services Constipation Action Plan can be freely downloaded at the following web link: https://wrnmmc.libguides.com/pediatrics/USAP
Study NCT05437523 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care without constipation action plan
Description: Standard of care without constipation action plan
Study NCT02072863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Study subjects will receive oprozomib administered orally.
Study NCT02072863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Study subjects will receive melphalan 9 mg/m2.
Study NCT02072863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Study subjects will receive prednisone 60 mg/m2.
Study NCT00548600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iridium Implant
Description: Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.
Study NCT00548600 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard external beam irradiation
Description: Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
Study NCT02625792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endo-Clot(TM)
Description: After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system. And treated with proton pump inhibitor as usual.
Study NCT02437253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline placebo
Study NCT01050790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.
Study NCT02904031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Study NCT02904031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT04641845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cork inlay wedge
Study NCT02366195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: The initial dose of talimogene laherparepvec is up to 4.0 mL of 10\^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10\^8 PFU/mL.
Study NCT02904031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-leucovorin
Study NCT02904031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Study NCT01599000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Description: fixed-dose tablet, six doses over three days, according to weight group
Study NCT01599000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination
Description: fixed-dose tablet, six doses over three days, according to weight group
Study NCT02318563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
Study NCT02318563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: A matching oral solution containing no cannabidiol
Study NCT01338818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin LA (methylphenidate hydrochloride extended release)
Description: Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
Study NCT02232217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy Sleep
Description: Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
Study NCT02232217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Control
Description: Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
Study NCT01495208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: intravitreal aflibercept injection 2mg
Study NCT02510625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomic Glenoid Reconstruction
Description: Distal tibia bone graft
Study NCT02510625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic bankart Repair
Description: Arthroscopic bankart Repair
Study NCT02507388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 3 mg/50 μL
Description: Administered as an intravitreal injection
Study NCT02507388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg/50 μL
Description: Administered as an intravitreal injection
Study NCT01721161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB033 (anti-LINGO-1 mAb)
Description: 100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
Study NCT01721161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
Study NCT02003326 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inflammatory markers
Study NCT00360412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Study NCT02753946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZTI-01
Description: 6g ZTI-01 intravenous infusion TID q8 hours
Study NCT02753946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-tazobactam
Description: 4.5g piperacillin-tazobactam intravenous infusion TID q8 hours
Study NCT04221724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise program
Description: The intervention consists of a combined multicomponent exercise program (EP) carried out for 6 months that includes strength, balance, flexibility and functional exercises aimed to improve functioning on daily life activities. The EP will be divided into two parts:~The first 3 months the EP aims to restore the physical condition through the multicomponent exercise program. This program will comprise of upper and lower body strengthening exercises, using external weights for 2-3sets of 8-12repetitions at a progressive intensity of 30-50% of 1RM. In addition, static balance and flexibility exercise will be performed.~From 3th to 6th months, the objective will be to improve autonomy through the functional EP. Strength exercises intensity will be increased to 60-70% of 1-RM, 2-3sets of 8-12repetitions. Attention tasks, temporal space dissociation and dynamic balance exercises will be added to increase the intensity in balance exercises. Flexibility and fine handle will be also performed
Study NCT03367728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: TAP and Rectus Sheath Block Injections of Ropivacaine
Study NCT03367728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: TAP and Rectus Sheath Block Injections of Normal Saline
Study NCT01014130 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HypoRT)
Description: Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.
Study NCT01014130 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally Fractionated Radiotherapy (ConRT)
Description: Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
Study NCT03626259 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Losartan and Amlodipine
Description: Losartan and amlodipine in fixed combination capsules, 100mg/5mg. One time daily with the first bite of eat meal per 8 weeks
Study NCT03626259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan capsules, 100mg. One time daily with the first bite of eat meal per 8 weeks
Study NCT02320916 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 23Gauge
Description: Arterial puncture will be made using a 23Gauge needle
Study NCT02320916 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25Gauge
Description: Arterial puncture will be made using a 25Gauge needle
Study NCT04001712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate
Description: caffeine citrate is given early to preterm neonates in need of respiratory support
Study NCT04001712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Citrate
Description: caffeine citrate is given early to preterm neonates in need of respiratory support
Study NCT00895284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic hysterectomy
Description: Robotic hysterectomy.
Study NCT00895284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hysterectomy
Description: Standard hysterectomy.
Study NCT04694690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self adhesive resin cement
Description: Self adhesive resin cement
Study NCT04694690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin cement
Description: Resin Cement system used after surface treatment
Study NCT04507243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active - HD tDCS
Description: Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
Study NCT00904046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg orally daily for 6 months
Study NCT00904046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally once a day for 6 months.
Study NCT05718466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT05718466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT05718466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Study NCT04507243 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham - HD tDCS
Description: Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
Study NCT00521287 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immune profiling and DC vaccine
Description: 1. For observational study (immune profiling): blood sampling 3-5 mL~2. For DC vaccine: one dose of DC vaccine(\~10 million cells)/2 week for at least 6 month or until progression.
Study NCT03435185 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injections
Description: Lidocaine injections. A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to greater occipital nerve and supraorbital nerve in the blockade patients.
Study NCT03435185 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline injections
Description: Saline injections. Patients received 2 ml 0.9% saline in bilaterally to greater occipital nerve and supraorbital nerve
Study NCT02271698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group
Study NCT02271698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.
Study NCT03107260 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: To evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in emergency surgery in elderly patients
Description: Evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in non-cardiac, thoracic and vascular emergency surgery in patients 65 years of age and older. The occurrence of POCD will be defined by the MMSE decrease of at least 4 points at 24, 48 or 72 hours
Study NCT04247230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine
Description: Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
Study NCT04247230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching placebo (PET500)
Description: Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
Study NCT04247230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STUD100
Description: Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
Study NCT02385851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-1701
Study NCT02385851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study NCT03790722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergometry H
Description: After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure.